Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Current Assets: 2022-2024

Historic Current Assets for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $54.4 million.

  • Corvus Pharmaceuticals' Current Assets rose 55.97% to $66.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.9 million, marking a year-over-year increase of 55.97%. This contributed to the annual value of $54.4 million for FY2024, which is 94.62% up from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Current Assets of $54.4 million as of FY2024, which was up 94.62% from $28.0 million recorded in FY2023.
  • In the past 5 years, Corvus Pharmaceuticals' Current Assets ranged from a high of $54.4 million in FY2024 and a low of $28.0 million during FY2023.
  • Its 3-year average for Current Assets is $42.0 million, with a median of $43.7 million in 2022.
  • Per our database at Business Quant, Corvus Pharmaceuticals' Current Assets crashed by 35.97% in 2023 and then spiked by 94.62% in 2024.
  • Yearly analysis of 3 years shows Corvus Pharmaceuticals' Current Assets stood at $43.7 million in 2022, then tumbled by 35.97% to $28.0 million in 2023, then spiked by 94.62% to $54.4 million in 2024.